View Filing Data

Document and Entity Information - USD ($)	9 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-KT
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	HSDT
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		91,246,676
Entity Public Float			$ 49,022,798

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Mar. 31, 2016
Current assets
Cash and cash equivalents	$ 2,668,655	$ 2,643,937
Receivables	225,155	399,106
Prepaid expenses and other current assets	556,456	997,679
Total current assets	3,450,266	4,040,722
TOTAL ASSETS	3,450,266	4,040,722
Current liabilities
Accounts payable and accrued liabilities	2,420,761	2,181,154
Shares to be issued	0	150,000
Derivative liability	4,473,800	1,725,760
Total current liabilities	6,894,561	4,056,914
TOTAL LIABILITIES	6,894,561	4,056,914
Commitments and contingencies	0	0
STOCKHOLDERS’ DEFICIT
Common stock (Unlimited Class A common shares authorized); (84,630,676 shares issued and outstanding as of December 31, 2016 and 72,193,209 shares issued and outstanding as of March 31, 2016)	30,897,064	24,347,930
Additional paid-in capital	5,731,508	2,940,539
Accumulated other comprehensive loss	(1,727,633)	(999,398)
Accumulated deficit	(38,345,234)	(26,305,263)
TOTAL STOCKHOLDERS’ DEFICIT	(3,444,295)	(16,192)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 3,450,266	$ 4,040,722

Consolidated Balance Sheets (Parenthetical) - shares	9 Months Ended	12 Months Ended
Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2016	Mar. 31, 2016
Statement Of Financial Position [Abstract]
Common Stock, Shares Authorized	Unlimited	Unlimited
Common Stock, Shares, Issued	84,630,676	72,193,209
Common Stock, Shares, Outstanding	84,630,676	72,193,209

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Operating expenses:
Research and development	$ 4,722,584	$ 2,664,063	$ 3,645,796
General and administrative	5,651,218	3,738,041	5,671,598
Total operating expenses	10,373,802	6,402,104	9,317,394
Operating loss	(10,373,802)	(6,402,104)	(9,317,394)
Other income (expense):
Interest and other income	110,611	123,741	103,330
Change in fair value of derivative liability	(2,479,905)	2,113,391	2,082,703
Foreign exchange gain (loss)	703,125	845,146	(18,785)
Gain on extinguishment of debt	0	268,334	268,334
Total other income (expense)	(1,666,169)	3,350,612	2,435,582
Net loss	(12,039,971)	(3,051,492)	(6,881,812)
Other comprehensive income (loss)
Foreign currency translation adjustments	(728,235)	(890,689)	(27,758)
Comprehensive loss	$ (12,768,206)	$ (3,942,181)	$ (6,909,570)
Net loss per share
Basic	$ (0.14)	$ (0.05)	$ (0.10)
Diluted	$ (0.14)	$ (0.06)	$ (0.12)
Weighted average shares outstanding
Basic	83,355,095	64,646,096	66,522,564
Diluted	83,355,095	65,180,918	67,026,544

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	First Financing Private Placement	Second Financing Private Placement	Third Financing Private Placement	Common Stock	Common Stock First Financing Private Placement	Common Stock Second Financing Private Placement	Common Stock Third Financing Private Placement	Additional Paid-In Capital	Shares to be Issued	Shares to be Issued Second Financing Private Placement	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance at Mar. 31, 2015	$ (1,562,901)				$ 16,358,093				$ 2,434,552	$ 39,545		$ (19,423,451)	$ (971,640)
Beginning Balance, Shares at Mar. 31, 2015					63,104,788
Exercise of finders' warrants	11,926				$ 11,926
Exercise of finders' warrants, Shares					14,400
Issuance of common stock for private placement		$ 1,465,524	$ 546,157	$ 233,806		$ 1,465,524	$ 585,702	$ 233,806			$ (39,545)
Issuance of common stock for private placement, Shares						849,273	335,463	125,756
Stock option exercise	42,500				$ 42,500
Stock option exercise, Shares					94,640
Fair value of options exercised					$ 20,454				(20,454)
Issuance of common stock as bonus shares	23,959				$ 23,959
Issuance of common stock as bonus shares, Shares					30,000
Issuance of common stock upon conversion of convertible note	1,525,000				$ 1,525,000
Issuance of common stock upon conversion of convertible note, Shares					2,083,333
Share issuance costs	(141,100)				$ (141,100)
Stock-based compensation	431,986								431,986
Fair value of non-employee vested options reallocated to derivative liability	(690,885)								(690,885)
Net loss	(3,051,492)											(3,051,492)
Foreign currency translation adjustments	(890,689)												(890,689)
Ending Balance at Dec. 31, 2015	(2,056,209)				$ 20,125,864				2,155,199			(22,474,943)	(1,862,329)
Ending Balance, Shares at Dec. 31, 2015					66,637,653
Beginning Balance at Mar. 31, 2015	(1,562,901)				$ 16,358,093				2,434,552	$ 39,545		(19,423,451)	(971,640)
Beginning Balance, Shares at Mar. 31, 2015					63,104,788
Exercise of finders' warrants	11,926				$ 11,926
Exercise of finders' warrants, Shares					14,400
Issuance of common stock for private placement		1,825,937	681,698	270,375		$ 1,825,937	$ 721,243	$ 270,375			$ (39,545)
Issuance of common stock for private placement, Shares						849,273	335,463	125,756
Fair value of warrants issued in connection with private placement, classified to derivative liability		$ (360,413)	$ (135,540)	$ (36,569)		$ (360,413)	$ (135,540)	$ (36,569)
Stock option exercise	42,500				$ 42,500
Stock option exercise, Shares					94,640
Fair value of options exercised					$ 34,378				(34,378)
Shares issued as a debt discount	29,045				$ 29,045
Shares issued as a debt discount, Shares					30,000
Issuance of common stock upon conversion of convertible note	1,731,667				$ 1,731,667
Issuance of common stock upon conversion of convertible note, Shares					2,083,333
Fair value of warrants issued in connection with initial borrowing under credit facility, classified to derivative liability	(206,667)				$ (206,667)
Issuance of common stock for draw down of remaining credit facility	5,000,000				$ 5,000,000
Issuance of common stock for draw down of remaining credit facility, Shares					5,555,556
Fair value of warrants issued in connection with draw down of remaining credit facility, classified to derivative liability	(796,945)				$ (796,945)
Share issuance costs	(141,100)				(141,100)
Stock-based compensation	1,231,250								1,231,250
Fair value of non-employee vested options reallocated to derivative liability	(690,885)								(690,885)
Net loss	(6,881,812)											(6,881,812)
Foreign currency translation adjustments	(27,758)												(27,758)
Ending Balance at Mar. 31, 2016	(16,192)				$ 24,347,930				2,940,539			(26,305,263)	(999,398)
Ending Balance, Shares at Mar. 31, 2016					72,193,209
Exercise of finders' warrants	$ 1,397,679				$ 1,548,863				(151,184)
Exercise of finders' warrants, Shares					1,825,600
Stock option exercise, Shares	210,000
Issuance of common stock in public offering and private placement	$ 6,547,997				$ 6,547,997
Issuance of common stock in public offering and private placement, Shares					10,305,125
Issuance of warrants in public offering and private placement	1,504,914								1,504,914
Share issuance costs	(1,508,919)				$ (1,875,190)				366,271
Stock-based compensation	1,461,646								1,461,646
Fair value of non-employee vested options reallocated to derivative liability	(268,135)								(268,135)
Agent compensation option exercise	581				$ 1,129				(548)
Agent compensation option exercise, Shares					750
Proceeds from the exercise of stock options and warrants	204,340				$ 326,335				(121,995)
Proceeds from the exercise of stock options and warrants, shares					305,992
Net loss	(12,039,971)											(12,039,971)
Foreign currency translation adjustments	(728,235)												(728,235)
Ending Balance at Dec. 31, 2016	$ (3,444,295)				$ 30,897,064				$ 5,731,508			$ (38,345,234)	$ (1,727,633)
Ending Balance, Shares at Dec. 31, 2016					84,630,676

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Cash flows from operating activities
Net loss	$ (12,039,971)	$ (3,051,492)	$ (6,881,812)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liability	2,479,905	(2,113,391)	(2,082,703)
Interest accretion	0	23,959	29,045
Stock-based compensation expense	1,461,646	431,986	1,231,250
Gain on extinguishment of debt	0	(268,334)	(268,334)
Unrealized foreign exchange loss (gain)	(641,485)	(901,518)	(120,876)
Changes in operating assets and liabilities:
Receivables	173,951	(119,567)	(390,273)
Prepaid expenses and other current assets	76,601	(384,629)	(91,644)
Accounts payable and accrued liabilities	604,228	128,457	487,935
Shares to be issued	0	0	150,000
Net cash used in operating activities	(7,885,125)	(6,254,529)	(7,937,412)
Cash flows from investing activities
Proceeds from the sale of short term investment	0	378,000	378,000
Net cash provided by investing activities	0	378,000	378,000
Cash flows from financing activities
Proceeds from the issuance of common stock and warrants	7,902,912	7,832,436	7,777,910
Share issuance costs	(1,508,919)	(141,100)	(141,000)
Proceeds from the exercise of stock options and warrants	1,602,600	0	54,426
Proceeds from issuance of convertible debt	0	2,000,000	2,000,000
Proceeds from issuance of promissory note	0	0	200,000
Repayment of promissory note	0	0	(200,000)
Net cash provided by financing activities	7,996,593	9,691,336	9,691,336
Effect of foreign exchange rate changes on cash	(86,750)	116,650	93,120
Net increase in cash and cash equivalents	24,718	3,931,457	2,225,044
Cash and cash equivalents at beginning of period	2,643,937	418,893	418,893
Cash and cash equivalents at end of period	2,668,655	4,350,350	2,643,937
Supplemental disclosure of non-cash cash activities
Cash paid for interest	0	1,644	1,651
Cash paid for income taxes	$ 0	$ 0	$ 0

Description of Business

9 Months Ended

Dec. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

1.	DESCRIPTION OF BUSINESS

Helius Medical Technologies, Inc. (the “Company”) is engaged primarily in the medical technology industry focused on neurological wellness. The Company’s planned principal operations include the development, licensing and acquisition of unique and non-invasive platform technologies to amplify the brain’s ability to heal itself. To date, the Company has not generated any revenue.

The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. The Company is based in Newtown, Pennsylvania.

The Company is currently listed on the Toronto Stock Exchange (the “TSX”). The Company began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol “HSM”, and subsequently moved to the TSX on April 18, 2016. The Company also began trading on the OTCQB under the ticker symbol “HSDT” on February 10, 2015.

On June 13, 2014, the Company completed its acquisition of 100% of the issued and outstanding shares of Neurohabilitation Corporation (“Neuro”), a private company incorporated in Delaware, USA, on January 22, 2013. Prior to the transaction, the Company was a non-operating public shell company. Accordingly, for financial reporting purposes, this transaction was deemed to be a capital transaction in substance and recorded as a reverse recapitalization of Neuro whereby Neuro is deemed to be the continuing, surviving entity for accounting purposes, but through reorganization, has deemed to have adopted the capital structure of the Company. Because the acquisition was considered a reverse recapitalization for accounting purposes, the combined historical financial statements of Neuro became the historical financial statements and from the completion of the acquisition on June 13, 2014, the financial statements have been prepared on a consolidated basis. The assets and liabilities of Neuro have been brought forward at their book value and no goodwill has been recognized in connection with the transaction.

On December 17, 2014, Neuro incorporated a wholly-owned subsidiary, Helius Medical Technologies (Canada), Inc. (“Helius Canada”). The financial information is presented in United States Dollars.

Going Concern

As of December 31, 2016, the Company had cash and cash equivalents of $2,668,655. During the nine months ended December 31, 2016, the Company incurred a net loss of $12,039,971 and, as of December 31, 2016 its accumulated deficit was $38,345,234. The Company has not generated any product revenues and has not achieved profitable operations. The Company expects to continue to incur operating losses and net cash outflows until such time as it generates a level of revenue to support its cost structure. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets.

Significant Accounting Policies

9 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies

2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosure of contingent assets and liabilities. Significant estimates include the assumptions used in the fair value pricing model for stock-based compensation and deferred income tax asset valuation allowances. Financial statements include estimates which, by their nature, are uncertain. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of Helius Medical Technologies, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an original maturity of three months or less.

Concentrations of Credit Risk

The Company is subject to credit risk in respect of its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.

Receivables

Receivable are stated at their net realizable value. As of December 31, 2016 and March 31, 2016 receivables consisted primarily of Goods and Services Tax (“GST”) and Quebec Sales Tax (“QST) refunds related to the Company’s Canadian expenditures.

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation expense using the straight-line method.

The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees will be measured at fair value on the date of the grant. The fair value of all stock options are expensed over their vesting period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Stock options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service condition.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date are measured and recognized at that date.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.

Foreign Currency

The functional currency of the Company and Helius Canada is the Canadian dollar (“CAD”) and the functional currency of Neuro is the U.S. dollar (“USD”). The Company’s reporting currency is the U.S. dollar. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiary at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in foreign exchange gain (loss) within the consolidated statements of operations and comprehensive loss. The foreign exchange adjustment in the books of Neuro relating to intercompany advances from Helius that are denominated in Canadian dollars is recorded in the consolidated statements of operations and comprehensive loss.

Income Taxes

The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 Income Taxes regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of the tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of operations and comprehensive loss.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, development and manufacturing of clinical trial devices and materials and supplies. R&D costs are charged to operations when they are incurred.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views their operations and manages their business in one segment.

Derivative Liabilities

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging. The result of this accounting treatment is that the fair value of the derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of operations and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current if the right to exercise or settle the derivative instrument lies with the holder.

Fair Value Measurements

The Company’s financial instruments consist primarily of cash and cash equivalents, receivables, accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company had certain Level 3 derivative liabilities required to be recorded at fair value on a recurring basis. Unobservable inputs used in the valuation of these liabilities includes volatility of the underlying share price and the expected term. See Note 5 for the inputs used in the Black-Scholes option pricing model as of December 31, 2016 and March 31, 2016 and the roll forward of the warrant liability and see Note 6 for the inputs used in the Black-Scholes option pricing model as of December 31, 2016 and March 31, 2016 for the roll forward of the derivative liability for non-employee stock options.

	Fair Value		Level 1		Level 2		Level 3
December 31, 2016
Liabilities:
Non-employee stock options	$	1,616,739		—		—	$	1,616,739
Warrants		2,857,061		—		—		2,857,061
March 31, 2016
Liabilities:
Non-employee stock options	$	521,179		—		—	$	521,179
Warrants		1,204,581		—		—		1,204,581

There were no transfers between any of the levels during the nine months ended December 31, 2016 or the year ended March 31, 2016.

Basic and Diluted Income (Loss) per Share

Earnings or loss per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted average of all potentially dilutive shares of common stock that were outstanding during the periods presented.

The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period.

EPS for convertible debt is calculated under the “if-converted” method. Under the if-converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.

The basic and diluted loss per share for the periods noted below is as follows:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Basic
Numerator
Net loss	$	(12,039,971	)	$	(6,881,812	)
Denominator
Weighted-average common shares outstanding		83,355,095			66,522,564
Basic net loss per share	$	(0.14	)	$	(0.10	)

Diluted
Numerator
Net loss, basic	$	(12,039,971	)	$	(6,881,812	)
Effect of dilutive securities: change in fair value of derivative liability		—			(1,156,002	)
Net loss, diluted	$	(12,039,971	)	$	(8,037,814	)
Denominator
Weighted average common shares outstanding		83,355,095			66,522,564
Effect of dilutive securities: stock options and warrants		—			503,980
Weighted average common shares outstanding		83,355,095			67,026,544
Diluted net loss per share	$	(0.14	)	$	(0.12	)

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Options outstanding		9,845,000		5,875,360
Warrants outstanding		10,086,262		12,973,009
Total		19,931,262		18,848,369

Reclassifications

Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update change existing guidance related to accounting for employee share-based payments affecting the income tax consequences of awards, classification of awards as equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the potential impact of the adoption of this standard.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. The updated accounting guidance was effective for the Company on December 31, 2016 and the Company has implemented this new accounting standard and updated its liquidity disclosures as necessary.

Promissory Note

9 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Promissory Note

3.	PROMISSORY NOTE

On August 25, 2015, the Company received $200,000 in exchange for the issuance of a promissory note. The promissory note was to be repaid six months from the date of issuance with interest accruing at the rate of 6% per annum. In addition, the lender was entitled to receive 30,000 common shares of the Company’s common stock on the date of the promissory note and an additional 30,000 common shares every three months thereafter as long as the principal of the loan remained outstanding.

On October 28, 2015, the Company repaid the loan in its entirety and issued 30,000 common shares that were owed the lender in accordance with the terms of the promissory note.

Convertible Note

9 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Convertible Note

4.	CONVERTIBLE NOTE

On October 9, 2015, in connection with an Asset Purchase Agreement, under which the Company licensed the use of its intellectual property in the People’s Republic of China, Taiwan, Singapore, Hong Kong, and the Macau Special Administrative Region, the Company entered into a US$7.0 million funding commitment with A&B Company Limited (“A&B”) in the form of a convertible promissory note. The funding commitment consisted of (i) an initial $2.0 million under the Note (“$2.0 million note” and (ii) an additional $5.0 million funding commitment, upon which the Company could draw down at any time or from time to time during the six-month period beginning on the issuance date of the promissory note. The $2.0 million note would accrue interest at a rate equal to 6% per annum, payable in cash on the due date of April 9, 2016. The $2.0 million note was unsecured and was convertible at the option of the holder into units of the Company at $0.96 per unit. Each unit would consist of one share of common stock and one half share purchase warrant exercisable at $1.44 for a period of three years from the date of issuance.

Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that the conversion feature embedded in the $2.0 Million Note was required to be bifurcated from the Note and accounted for as a derivative liability because it was considered not to be indexed to the Company’s stock due to its exercise price being denominated in a currency other than the Company’s functional currency. Therefore, pursuant to the guidance of ASC 815-15, the Company allocated the proceeds from the issuance of the $2.0 million note first to the fair value of the embedded conversion feature, with a corresponding discount allocated to the Note. This resulted in a debt discount of $425,208. This debt discount would be amortized using the effective interest method over the term of the $2.0 million note. During the year ended March 31, 2016, the Company did not record any accretion in respect of this discount, because the $2.0 million note was immediately converted, as noted below.

On October 9, 2015, the Company received the conversion notice and on November 10^th, 2015, the Company issued 2,083,333 shares of common stock at a price of $0.96 per share and 1,041,667 warrants exercisable at $1.44 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on November 10, 2015. Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that the warrants are required to be accounted for as liabilities because they are considered not to be indexed to the Company’s stock due to the exercise price being denominated in a currency other than the Company’s functional currency. The fair value of these warrants was determined to be $206,667 using the Black-Scholes option pricing model. See Note 5. for the derivative liability roll forward.

As a result of the bifurcation of the embedded conversion option, for accounting purposes, two instruments were considered outstanding and, upon exercise of the contractual conversion option, extinguishment accounting has been applied. Consequently, the shares issued pursuant to the conversion are recorded at their fair value on the date of issuance, determined with reference to their quoted market price on the date of conversion. The resulting difference between the fair value of the shares issued, less the fair value of the related conversion feature and the carrying value of the related debt, is recorded as a gain or loss on the consolidated statement of operations. During the year ended March 31, 2016, the Company recorded a gain on extinguishment of debt of $268,334 in connection with the conversion of the Note.

The Company could elect to draw down on the additional $5.0 million funding through the issuance of units of the Company at a price based on the volume weighted average closing price of the Company’s shares of common stock on the date the Company elects to draw down from the commitment (the “Draw Down Price”). Each unit would consist of one shares of common stock of the Company and one half share purchase warrant. The warrant would be exercisable at the price representing a fifty percent (50%) premium to the Draw Down Price.

On December 29, 2015, the Company drew down the remaining $5.0 million commitment through the issuance of 5,555,556 shares of common stock at a price of $0.90 per share and 2,777,778 warrants exercisable at $1.35 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on January 7, 2016.

Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that the warrants are required to be accounted for as liabilities because they are considered not to be indexed to the Company’s stock due to the exercise price being denominated in a currency other than the Company’s functional currency. Consequently, the Company allocated the proceeds from the $5.0 million funding initially to the warrants at their fair value, with the remainder allocated to the common shares. The fair value of these warrants was determined to be $796,945 using the Black Scholes option pricing model. See Note 5. for the derivative liability roll-forward relating to these warrants.

Common Stock and Warrants

9 Months Ended

Dec. 31, 2016

Equity [Abstract]

Common Stock and Warrants

5.	COMMON STOCK AND WARRANTS

As of December 31, 2016, the Company’s certificate of incorporation authorized the Company to issue unlimited Class A common shares without par value. Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. No dividends have been declared through December 31, 2016. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

The Company is subject to a stockholders’ agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

Upon completion of the Recapitalization on June 13, 2014, the Company issued a total of 35,300,083 shares to the shareholders of Neuro. In connection with the Recapitalization, the Company also closed a non-brokered private placement (the “Private Placement”) at CAD $0.50 per unit of 15,240,000 units raising $7,016,002 on May 30, 2014. Each unit consists of one common stock of the Company and one half of a warrant of the Company where one full warrant is exercisable for 2 years at CAD $1.00 into one common stock. The fair value of the warrants issued was determined using the Black Scholes option-pricing model and the Company used the relative fair value method to allocate $578,961 of the gross proceeds to Additional Paid-in Capital to account for the warrants issued.

On April 30, 2015, the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015, the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

On July 17, 2015, the Company closed a non-brokered private placement (the “Third Financing”) raising gross proceeds of $270,375 by the issuance of 125,756 units (each a “Third Financing Unit”) at a price of $2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder’s fee of $16,223 in connection with this Third Financing, as well as 7,545 finder’s warrants (the “Third Financing Finder’s Warrants”). Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

On November 10, 2015, upon conversion of the $2.0 million Note, the Company issued 2,083,333 shares of common stock at a price of $0.96 per share and 1,041,667 warrants exercisable at $1.44 for a period of three years from the date of issuance.

On April 18, 2016, the Company closed its short form prospectus offering in Canada and a concurrent U.S. private placement (the “Offering”) of units (the “Units”) with gross proceeds to the Company of USD $7,184,190 through the issuance of Units at a price of CAD$1.00 per Unit. Each Unit consists of one Class A common share in the capital of the Company (a “Common Share’) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each warrant entitles the holder thereof to acquire one additional Common Share at an exercise price of CAD$1.50 on or before April 18, 2019. Mackie Research Capital Corporation (the “Agent”) acted as agent and sole bookrunner in connection with the Offering. The Company paid the Agent a cash commission of USD $340,250 and has granted to the Agent compensation options exercisable to purchase 436,050 Units at an exercise price of CAD$1.00 per Unit for a period of 24 months from the closing of the Offering. The Company incurred other cash issuance costs of USD $1,116,545 related to this offering.

On May 2, 2016, the Company closed the sale of the additional units issued pursuant to the exercise of the over-allotment option (“Over-Allotment Option”) granted to the Agent in connection with the Offering. The Offering was made pursuant to a short form prospectus filed with the securities regulatory authorities in each of the provinces of Canada, except Québec. Pursuant to the exercise of the Over-Allotment Option, the Company issued an additional 1,090,125 Units (the "Over-Allotment Units") at a price of CAD $1.00 per Over-Allotment Unit for additional gross proceeds to the Company of USD $868,721, bringing the total aggregate gross proceeds to the Company under the Offering to USD $8,052,911. Each Over-Allotment Unit consists of one Class A common share in the capital of the Company (an “Over-Allotment Common Share”) and one half of one Common Share purchase warrant (each whole warrant, an “Over-Allotment Warrant”). Each Over-Allotment Warrant entitles the holder thereof to acquire one additional Over-Allotment Common Share at an exercise price of CAD $1.50 on or before April 18, 2019. In connection with the closing of the Over-Allotment Option, the Company paid the Agent a cash commission of USD $52,124 and granted to the Agent compensation options exercisable to purchase 65,407 Over-Allotment Units at an exercise price of CAD $1.00 per Over-Allotment Unit for a period of 24 months from the closing of this Offering.

The warrants issued in each of the April 18, 2016 and May 2, 2016 closings are classified within equity. The proceeds from the Offering were allocated on a relative fair value basis between the Class A common shares and the warrants issued. The compensation options are accounted for as warrants. These warrants represent additional share issuance costs and are recorded within equity at their fair value.

The fair value of the warrants granted during the nine months ended December 31, 2016 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2016
Stock price	$1.09 CAD
Exercise price	$1.50 CAD
Expected life	3.0 years
Expected volatility		83.83	%
Risk-free interest rate		0.60	%
Dividend rate		0.00	%

The fair value of the compensation options granted during the nine months ended December 31, 2016 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2016
Stock price	$1.36 CAD
Exercise price	$1.00 CAD
Expected life	2.0 years
Expected volatility		126.76	%
Risk-free interest rate		0.61	%
Dividend rate		0.00	%

The weighted average fair value of the warrants issued during the nine months ended December 31, 2016 was CAD$0.50 per share.

The weighted average fair value of the compensation options issued during the nine months ended December 31, 2016 was CAD$0.93 per share.

On June 6, 2016, the Company received proceeds of USD $1,397,679 from the exercise of 1,825,600 outstanding warrants which were issued in connection with the Company’s private placement of subscription receipts that closed on May 30, 2014. The remaining 6,604,400 warrants issued in this offering expired unexercised.

Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that all of the warrants issued during the year ended March 31, 2016 as described above are required to be accounted for as liabilities because they are considered not to be indexed to the Company’s stock due to the exercise price being denominated in a currency other than the Company’s functional currency. Consequently, the Company determined the fair value of each warrant issuance using the Black-Scholes option pricing model, with the remainder of the proceeds allocated to the common shares.

The warrants having an exercise price denominated in a currency other than the functional currency of the Company that are required to be accounted for as liabilities are summarized as follows for nine months ended December 31, 2016 and the year ended March 31, 2016:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Fair value of warrants at beginning of period	$	1,204,581	$	—
Issuance of warrants		—		1,536,134
Change in fair value of warrants during the period		1,652,480		(331,553	)
Fair value of warrants at end of period	$	2,857,061	$	1,204,581

The warrants are required to be re-valued with the change in fair value of the liability recorded as a gain or loss in the change of fair value of derivative liability, included in other income (expense) in the Company’s consolidated statements of operations and comprehensive loss. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The fair value of warrants as of December 31, 2016 and March 31, 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2016			March 31, 2016
Stock price	$	1.38		$	0.78
Exercise price	$	1.62		$	1.62
Expected life	1.89 years			2.65 years
Expected volatility		94.97	%		83.86	%
Risk-free interest rate		0.79	%		0.83	%
Dividend rate		0.00	%		0.00	%

The following is a summary of warrant activity during the nine months ended December 31, 2016:

	Number of Warrants					Weighted-Average Exercise Price
	CAD			US		CAD		US
Outstanding as of April 1, 2016		8,430,000			4,528,609	$	1.00	$	1.62
Granted		5,152,938			—		1.50
Granted (Agent Compensation)		501,457			—		1.00
Expired		(6,604,400	)		—		1.00
Exercised		(1,922,342	)		—		1.02
Outstanding as of December 31, 2016		5,557,653			4,528,609	$	1.46	$	1.62

The warrants outstanding and exercisable as of December 31, 2016 were as follows:

Number of Warrants Outstanding		Exercise Price	Expiration Date
	452,032	US$3.00	April 30, 2018
	167,731	US$3.00	June 26, 2018
	18,978	US$2.15	June 26, 2020
	62,878	US$3.00	July 17, 2018
	7,545	US$2.15	July 17, 2020
	1,041,667	US$1.44	November 10, 2018
	2,777,778	US$1.35	December 29, 2018
	5,056,946	CAD$1.50	April 18, 2019
	500,707	CAD$1.00	April 18, 2018

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Share Based Payments

9 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share Based Payments

6.	SHARE BASED PAYMENTS

On June 18, 2014, the Company’s Board of Directors authorized and approved the adoption of the 2014 Stock Incentive Plan (“2014 Plan”), under which an aggregate of 12,108,016 shares of common stock may be issued. Pursuant to the terms of the 2014 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units and deferred stock units. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Company’s Board of Directors.

On August 8, 2016, the Company’s Board of Directors authorized and approved the adoption of the 2016 Omnibus Incentive Plan (“2016 Plan”), under which an aggregate of 15,000,000 shares of common stock may be issued. Pursuant to the terms of the 2016 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units, stock equivalent units and performance based cash awards. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Company’s Board of Directors.

As of December 31, 2016, there were an aggregate of 16,958,376 shares of common stock remaining available for grant under the 2014 and the 2016 Plan.

The following is a summary of stock option activity during nine months ended December 31, 2016:

				Weighted Average		Aggregate
				Exercise Price		Intrinsic Value
	Number of Options			(CAD)		(CAD)
Outstanding as of April 1, 2016		6,675,360		$	1.08	$	1,580,883
Granted		3,535,000			1.38
Forfeited		(31,250	)		0.60
Cancelled		(124,110	)		0.60
Exercised		(210,000	)		0.60
Outstanding as of December 31, 2016		9,845,000			1.20		8,218,150
Exercisable as of December 31, 2016		6,763,502		$	1.16	$	6,243,040

The aggregate intrinsic value of stock options exercised during the nine months ended December 31, 2016 and the year ended March 31, 2016 was $117,530 and $19,832, respectively.

The stock options outstanding and exercisable as of December 31, 2016 were as follows:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	3,310,000	June 18, 2019		2.46	$	0.60	$	0.26		3,310,000
	100,000	July 14, 2017		0.53	$	2.52	$	1.05		100,000
	450,000	December 8, 2019		2.94	$	2.92	$	1.65		450,000
	100,000	December 8, 2019		2.94	$	2.92	$	1.31		100,000
	400,000	December 8, 2019		2.94	$	2.96	$	1.29		400,000
	100,000	March 16, 2020		3.21	$	3.20	$	1.42		66,667
	50,000	August 15, 2015		3.62	$	0.98	$	0.39		33,334
	750,000	October 21, 2020		3.81	$	0.87	$	0.36		375,000
	550,000	October 28, 2020		3.83	$	0.84	$	0.44		550,000
	400,000	October 28, 2020		3.83	$	0.84	$	0.36		176,000
	100,000	December 31, 2020		4.00	$	1.24	$	0.50		66,668
	3,025,000	July 13, 2020		3.53	$	1.39	$	0.65		1,008,333
	100,000	August 8, 2020		3.61	$	1.31	$	0.65		25,000
	410,000	October 3, 2020		3.76	$	1.35	$	0.80		102,500
	9,845,000									6,763,502

Included in the table above are non-employee awards that are subject to re-measurement each reporting period until vested. As a result, the grant date fair value is not representative of the total expense that will be recorded for these awards. As of December 31, 2016, the unrecognized compensation cost related to non-vested stock options outstanding, was $1,263,767 to be recognized over a weighted-average remaining vesting period of approximately 1.41 years. The Company recognizes compensation expense for only the portion of awards that are expected to vest. During the nine months ended December 31, 2016 and the year ended March 31, 2016, the Company applied an expected forfeiture rate of 0% based on its historical experience.

The fair value of the employee and director stock options granted during the nine months ended December 31, 2016 and the year ended March 31, 2016 were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Stock price	$1.39 CAD			$0.82 CAD
Exercise price	$1.39 CAD			$0.87 CAD
Expected life	2.5 years			3.75 years
Expected volatility		77.92	%		67.85	%
Risk-free interest rate		0.49	%		0.63	%
Dividend rate		0.00	%		0.00	%

The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history. The Company recognizes stock-based compensation expense for only the portion of awards that are expected to vest. During the nine months ended December 31, 2016 and the year ended March 31, 2016, the Company applied an expected forfeiture rate of 0% based on its historical experience.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the stock options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are re-measured at their respective fair values at each reporting period and accounted for as equity awards until the terms associated with their vesting requirements have been met. The changes in fair value of the unvested non-employee awards are reflected in their respective operating expense classification in the Company’s consolidated statements of operations and comprehensive loss.

The non-employee stock options that are accounted for as liabilities are summarized as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Fair value of non-employee stock options at beginning of period	$	521,179	$	1,581,444
Reallocation of vested non-employee stock options		268,135		690,885
Change in fair value of non-employee stock options during the period		827,425		(1,751,150	)
Fair value of non-employee stock options at end of period	$	1,616,739	$	521,179

The non-employee stock options that have vested are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the stock options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The fair value of non-employee liability classified awards as of December 31, 2016 and March 31, 2016 were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	December 31, 2016			March 31, 2016
Stock price	$1.92 CAD			$0.97 CAD
Exercise price	$1.23 CAD			$1.52 CAD
Expected life	2.59 years			3.23 years
Expected volatility		87.61	%		84.62	%
Risk-free interest rate		0.79	%		0.53	%
Dividend rate		0.00	%		0.00	%

Stock-based compensation expense is classified in the Company’s statements of operations and comprehensive loss as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Research and development	$	106,932	$	158,396
General and administrative		1,354,714		1,072,854
	$	1,461,646	$	1,231,250

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

9 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

7.	INCOME TAXES

The components of net loss are as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
U.S	$	11,081,757	$	5,132,611
Non-U.S.		958,214		1,749,201
	$	12,039,971	$	6,881,812

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision is as follows:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Statutory tax rate		34.00	%		34.00	%
Net loss before income taxes	$	12,039,971		$	(6,882,812	)
Expected income tax recovery	$	(4,093,591	)	$	(2,340,000	)
Increase (decrease) in income tax recovery resulting from:
Derivative liability		843,168			(708,000	)
Share based payments		467,183			419,000
Other permanent difference		(419,782	)		49,000
Effect of change in statutory rate		—			(147,000	)
Effect of over provision in prior year		—			(2,164,000	)
Foreign income taxed at foreign rate		76,654			100,000
Increase in valuation allowance		3,126,368			4,791,000
Income tax expense	$	—		$	—

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows:

	December 31, 2016			March 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$	7,626,208		$	4,915,000
Tax credits		702,153			—
Stock compensation		1,726,293			1,725,000
Other		169,968			609,000
Valuation allowance		(10,224,622	)		(7,249,000	)
Net deferred income tax asset	$	—		$	—

As of December 31, 2016, the Company has accumulated non-capital losses totaling $2,707,393 in Canada and net operating losses of $21,335,527 in the U.S., which may be available to carry forward and offset future years’ taxable income. The losses expire in various amounts starting in 2033.

Under the provisions of the Internal Revenue Code, the net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Section 382 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.

Uncertain Tax Positions

The Company has adopted certain provisions of ASC 740, “Income Taxes”, which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions taken or expected to be taken in income tax returns. The provisions also provide guidance on the de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions.

The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the expiration of the respective statutes of limitation. The Company currently has no tax years under examination.

At December 31, 2016, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

Commitments and Contingencies

9 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

8.	COMMITMENTS AND CONTINGENCIES

(a)

On January 22, 2013, the Company entered into a license agreement with Advanced NeuroRehabilitation, LLC (“ANR”) for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares of common stock, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology. The Company has not made any royalty payments to date under this agreement.

(b)

On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica, LLC (“Ximedica”) where Ximedica will design, develop and produce the PoNS™ product solution suitable for clinical trial and commercial sale. The multi-phased development program contains total contracted amounts of $5,900,000, of which $6,959,784 was expensed as research and development expense since inception through December 31, 2016. Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. During the nine months ended December 31, 2016 and the year ended March 31, 2016, the Company incurred R&D charges of $1,647,968 and $120,448 pursuant to this agreement. As the development agreement progresses, the Company expects to contract for additional phases.

(c)

Under the Company’s Asset Purchase Agreement with A&B, if the Company fails to obtain FDA marketing authorization for commercialization of or otherwise fail to ensure that the PoNS™ device is available for purchase by the U.S. Government by December 31, 2017, the Company is subject to a $2,000,000 contract penalty payable to A&B, unless the Company receives an exemption for the requirement of FDA marketing authorization from the US Army Medical Material Agency. The Company has determined that the possibility of an economic outlay under this contractual penalty is remote.

(d)

In November 2014, the Company signed a development and distribution agreement with Altair LLC to apply for registration and distribution of the PoNS™ device in the territories of the former Soviet Union. The Company will receive 7% royalty on sales of the devices within the territories. However, there is no assurance that such commercialization will occur.

Related Party Transactions

9 Months Ended

Dec. 31, 2016

Related Party Transactions

9.	RELATED PARTY TRANSACTIONS

During the nine months ended December 31, 2016 and the year ended March 31, 2016, the Company paid $97,829 and $64,210 in consulting fees to certain directors of the Company, respectively. As of December 31, 2016 and March 31, 2016, the Company owed $2,550 and $3,450 to a director for consulting services, respectively.

During April 2016, the Company entered into a consulting agreement with Montel Media, Inc. (“Montel Media”), pursuant to which Montel Media provides consulting services for the promotion of the Company’s clinical trials and ongoing media and marketing strategies. Under the agreement, Montel Media receives $15,000 per month. During the nine months ended December 31, 2016, the Company paid Montel Media $135,000 pursuant to the consulting agreement. Montel Media is owned by Montel Williams, who serves on the board of MPJ Healthcare, LLC, which beneficially owns greater than 5% of the Company’s common stock.

During the nine months ended December 31, 2016 and the year ended March 31, 2016, an expense of $648,208 and a benefit of $195,709, respectively. was included in the change in fair value of derivative liabilities as the fair value of stock-based compensation attributed to the options granted to two directors and a consultant for consulting services rendered with respect to the design and development of the PoNS™ device.

Sole-Source Cost-Sharing Agreement

9 Months Ended

Dec. 31, 2016

Disclosure Of Cost Sharing Agreement [Abstract]

Sole-Source Cost-Sharing Agreement

10.	SOLE-SOURCE COST-SHARING AGREEMENT

During the year ended March 31, 2016, the Company entered into a sole source cost sharing contract executed with the U.S. Army Medical Research and Material Command (“USAMRMC”). Under the terms of the contract, the USAMRMC will reimburse the Company up to a maximum of $2,996,244 for the registrational trial (“the trial”) investigating the safety and effectiveness of the PoNS^TM device for mild- to moderate-traumatic brain injury. The original contract expired on December 31, 2016; however, the Company has extended the contract with the USAMRMC through December 31, 2017 with reimbursement of expenses based on a milestone schedule of subjects completing the trial based on the current trial forecast timelines. As of December 31, 2016, the Company has received a total of $1,818,249 in respect of expenses reimbursed. All reimbursement amounts received are credited directly to the accounts in which the original expense is recorded, including research and development, wages and salaries, and legal expenses.

Supplemental Cash Flow Information

9 Months Ended

Dec. 31, 2016

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

11.	SUPPLEMENTAL CASH FLOW INFORMATION

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the consolidated statements of cash flows.

During the nine months ended December 31, 2016:

Fair value of warrants issued to agent for services provided in conjunction with the Offering was $366,271.

ii)

Proceeds from the issuance of common stock excludes $150,000 that was received prior to April 1, 2016.

During the year ended March 31, 2016:

Fair value of warrants issued in conjunction with private placements in April, June and July 2015 was $532,522.

ii)

Fair value of warrants issued in conjunction with A&B credit facility (including upon conversion of $2.0 million convertible note and draw down of $5.0 million) was $1,003,612.

iii)

The Company issued 30,000 shares of common stock having a fair value of $29,045 based on the quoted market price as a bonus in connection with the issuance of a promissory note;

iv)

A gain on extinguishment of debt of $268,334 based on the difference between the fair value of the shares issued to settle the A&B credit facility and the fair value of the related conversion feature and the carrying value of the related debt.

During the nine months ended December 31, 2015:

The Company issued 30,000 shares of common stock having a fair value of $23,959 based on their quoted market price as a bonus in connection with the advance of a loan.

ii)

The Company issued $2,083,333 common shares having a fair value of $1,525,000 based on their quoted market price upon the conversion of a convertible note payable in the amount of $2,000,000. Also, in connection with this debt conversion, the Company also issued 1,041,667 share purchase warrants having a fair value of $206,667 at their inception.

iii)

The Company reallocated $690,885 from additional paid-in capital to derivative liability in respect of the fair value of non-employee share purchase options that had vested.

Subsequent Events

12 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

12.	SUBSEQUENT EVENTS

In February 2017, the Company issued 6,555,000 shares of common stock and raised a total of CAD$12,454,500, net of issuance costs through an underwritten registered public offering. The Company intends to use the net proceeds from the offering to fund investment in PoNS™ research and development, including the completion of its ongoing registrational trial in mild- to moderate-traumatic brain injury, the launch of a registrational clinical trial in multiple sclerosis and an additional clinical trial in cognition, research and development activities to complete the Company’s FDA submission and for working capital and general corporate purposes.

On February 14, 2017, Mackie Research Capital Corporation (“Mackie”), a Canadian investment banking firm, filed a statement of claim in the Ontario Superior Court of Justice naming the Company as defendant. The claim alleges that the Company breached a term of the agency agreement dated March 23, 2016 between the Company and Mackie in connection with its public offering of Class A Common Stock, which closed on February 16, 2017 by not complying with Mackie’s right of first refusal to serve as the lead underwriter in the offering. The Company believes that it fully complied with its obligations under the agency agreement by offering Mackie the opportunity to serve as lead underwriter in the offering. The claim seeks damages totaling $1,400,000 and equitable relief. As the matter is at a preliminary stage, the Company has not been able to make a full assessment on the merits of the claim. The Company intends to defend itself vigorously.

In March 2017, the Company entered into a lease for 10,444 square feet of dedicated office space at 642 Newtown-Yardley Road, Suite 100, Newtown, PA 18940. The lease commences on July 1, 2017 and terminates on December 31, 2022 with an option to extend until 2027. Monthly rent plus utilities is approximately $20,018 per month with a 3% annual increase.

Significant Accounting Policies (Policies)

9 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Going Concern

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

Principles of Consolidation

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an original maturity of three months or less.

Concentrations of Credit Risk

Receivables

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation expense using the straight-line method.

Foreign Currency

Income Taxes

Research and Development Expenses

Segment Information

Derivative Liabilities

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities;

	Fair Value		Level 1		Level 2		Level 3
December 31, 2016
Liabilities:
Non-employee stock options	$	1,616,739		—		—	$	1,616,739
Warrants		2,857,061		—		—		2,857,061
March 31, 2016
Liabilities:
Non-employee stock options	$	521,179		—		—	$	521,179
Warrants		1,204,581		—		—		1,204,581

There were no transfers between any of the levels during the nine months ended December 31, 2016 or the year ended March 31, 2016.

Basic and Diluted Income (Loss) per Share

The basic and diluted loss per share for the periods noted below is as follows:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Basic
Numerator
Net loss	$	(12,039,971	)	$	(6,881,812	)
Denominator
Weighted-average common shares outstanding		83,355,095			66,522,564
Basic net loss per share	$	(0.14	)	$	(0.10	)

Diluted
Numerator
Net loss, basic	$	(12,039,971	)	$	(6,881,812	)
Effect of dilutive securities: change in fair value of derivative liability		—			(1,156,002	)
Net loss, diluted	$	(12,039,971	)	$	(8,037,814	)
Denominator
Weighted average common shares outstanding		83,355,095			66,522,564
Effect of dilutive securities: stock options and warrants		—			503,980
Weighted average common shares outstanding		83,355,095			67,026,544
Diluted net loss per share	$	(0.14	)	$	(0.12	)

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Options outstanding		9,845,000		5,875,360
Warrants outstanding		10,086,262		12,973,009
Total		19,931,262		18,848,369

Reclassifications

Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

9 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Derivative Liability for Non-employee Stock Options

	Fair Value		Level 1		Level 2		Level 3
December 31, 2016
Liabilities:
Non-employee stock options	$	1,616,739		—		—	$	1,616,739
Warrants		2,857,061		—		—		2,857,061
March 31, 2016
Liabilities:
Non-employee stock options	$	521,179		—		—	$	521,179
Warrants		1,204,581		—		—		1,204,581

Summary of Basic and Diluted Loss per Share

The basic and diluted loss per share for the periods noted below is as follows:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Basic
Numerator
Net loss	$	(12,039,971	)	$	(6,881,812	)
Denominator
Weighted-average common shares outstanding		83,355,095			66,522,564
Basic net loss per share	$	(0.14	)	$	(0.10	)

Diluted
Numerator
Net loss, basic	$	(12,039,971	)	$	(6,881,812	)
Effect of dilutive securities: change in fair value of derivative liability		—			(1,156,002	)
Net loss, diluted	$	(12,039,971	)	$	(8,037,814	)
Denominator
Weighted average common shares outstanding		83,355,095			66,522,564
Effect of dilutive securities: stock options and warrants		—			503,980
Weighted average common shares outstanding		83,355,095			67,026,544
Diluted net loss per share	$	(0.14	)	$	(0.12	)

Summary of Outstanding Securities Excluded from Computation of Diluted Weighted Shares Outstanding

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Options outstanding		9,845,000		5,875,360
Warrants outstanding		10,086,262		12,973,009
Total		19,931,262		18,848,369

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Common Stock and Warrants (Tables)

9 Months Ended

Dec. 31, 2016

Equity [Abstract]

Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

The fair value of the warrants granted during the nine months ended December 31, 2016 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2016
Stock price	$1.09 CAD
Exercise price	$1.50 CAD
Expected life	3.0 years
Expected volatility		83.83	%
Risk-free interest rate		0.60	%
Dividend rate		0.00	%

The fair value of warrants as of December 31, 2016 and March 31, 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2016			March 31, 2016
Stock price	$	1.38		$	0.78
Exercise price	$	1.62		$	1.62
Expected life	1.89 years			2.65 years
Expected volatility		94.97	%		83.86	%
Risk-free interest rate		0.79	%		0.83	%
Dividend rate		0.00	%		0.00	%

Fair Value of Compensation Options Granted Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

	December 31, 2016
Stock price	$1.36 CAD
Exercise price	$1.00 CAD
Expected life	2.0 years
Expected volatility		126.76	%
Risk-free interest rate		0.61	%
Dividend rate		0.00	%

Summary of Warrants Exercise Price Accounted for Liabilities

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Fair value of warrants at beginning of period	$	1,204,581	$	—
Issuance of warrants		—		1,536,134
Change in fair value of warrants during the period		1,652,480		(331,553	)
Fair value of warrants at end of period	$	2,857,061	$	1,204,581

Summary of Warrant Activity

The following is a summary of warrant activity during the nine months ended December 31, 2016:

	Number of Warrants					Weighted-Average Exercise Price
	CAD			US		CAD		US
Outstanding as of April 1, 2016		8,430,000			4,528,609	$	1.00	$	1.62
Granted		5,152,938			—		1.50
Granted (Agent Compensation)		501,457			—		1.00
Expired		(6,604,400	)		—		1.00
Exercised		(1,922,342	)		—		1.02
Outstanding as of December 31, 2016		5,557,653			4,528,609	$	1.46	$	1.62

Warrants Outstanding and Exercisable

The warrants outstanding and exercisable as of December 31, 2016 were as follows:

Number of Warrants Outstanding		Exercise Price	Expiration Date
	452,032	US$3.00	April 30, 2018
	167,731	US$3.00	June 26, 2018
	18,978	US$2.15	June 26, 2020
	62,878	US$3.00	July 17, 2018
	7,545	US$2.15	July 17, 2020
	1,041,667	US$1.44	November 10, 2018
	2,777,778	US$1.35	December 29, 2018
	5,056,946	CAD$1.50	April 18, 2019
	500,707	CAD$1.00	April 18, 2018

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share Based Payments (Tables)

9 Months Ended

Dec. 31, 2016

Summary of Stock Option Activity

The following is a summary of stock option activity during nine months ended December 31, 2016:

				Weighted Average		Aggregate
				Exercise Price		Intrinsic Value
	Number of Options			(CAD)		(CAD)
Outstanding as of April 1, 2016		6,675,360		$	1.08	$	1,580,883
Granted		3,535,000			1.38
Forfeited		(31,250	)		0.60
Cancelled		(124,110	)		0.60
Exercised		(210,000	)		0.60
Outstanding as of December 31, 2016		9,845,000			1.20		8,218,150
Exercisable as of December 31, 2016		6,763,502		$	1.16	$	6,243,040

Summary of Stock Options Outstanding and Exercisable

The stock options outstanding and exercisable as of December 31, 2016 were as follows:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	3,310,000	June 18, 2019		2.46	$	0.60	$	0.26		3,310,000
	100,000	July 14, 2017		0.53	$	2.52	$	1.05		100,000
	450,000	December 8, 2019		2.94	$	2.92	$	1.65		450,000
	100,000	December 8, 2019		2.94	$	2.92	$	1.31		100,000
	400,000	December 8, 2019		2.94	$	2.96	$	1.29		400,000
	100,000	March 16, 2020		3.21	$	3.20	$	1.42		66,667
	50,000	August 15, 2015		3.62	$	0.98	$	0.39		33,334
	750,000	October 21, 2020		3.81	$	0.87	$	0.36		375,000
	550,000	October 28, 2020		3.83	$	0.84	$	0.44		550,000
	400,000	October 28, 2020		3.83	$	0.84	$	0.36		176,000
	100,000	December 31, 2020		4.00	$	1.24	$	0.50		66,668
	3,025,000	July 13, 2020		3.53	$	1.39	$	0.65		1,008,333
	100,000	August 8, 2020		3.61	$	1.31	$	0.65		25,000
	410,000	October 3, 2020		3.76	$	1.35	$	0.80		102,500
	9,845,000									6,763,502

Summary of Non-Employee Stock Options Accounted for As Liabilities

The non-employee stock options that are accounted for as liabilities are summarized as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Fair value of non-employee stock options at beginning of period	$	521,179	$	1,581,444
Reallocation of vested non-employee stock options		268,135		690,885
Change in fair value of non-employee stock options during the period		827,425		(1,751,150	)
Fair value of non-employee stock options at end of period	$	1,616,739	$	521,179

Summary of Stock Based Compensation Expense is Classified in Statement of Operations and Comprehensive Loss

Stock-based compensation expense is classified in the Company’s statements of operations and comprehensive loss as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
Research and development	$	106,932	$	158,396
General and administrative		1,354,714		1,072,854
	$	1,461,646	$	1,231,250

Employee and Director Stock Options [Member]

Estimation Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Stock price	$1.39 CAD			$0.82 CAD
Exercise price	$1.39 CAD			$0.87 CAD
Expected life	2.5 years			3.75 years
Expected volatility		77.92	%		67.85	%
Risk-free interest rate		0.49	%		0.63	%
Dividend rate		0.00	%		0.00	%

Non-Employee Stock Option [Member]

Estimation Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions

	December 31, 2016			March 31, 2016
Stock price	$1.92 CAD			$0.97 CAD
Exercise price	$1.23 CAD			$1.52 CAD
Expected life	2.59 years			3.23 years
Expected volatility		87.61	%		84.62	%
Risk-free interest rate		0.79	%		0.53	%
Dividend rate		0.00	%		0.00	%

Income Taxes (Tables)

9 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Components of Net Loss for Income Tax

The components of net loss are as follows:

	Nine Months Ended December 31, 2016		Year Ended March 31, 2016
U.S	$	11,081,757	$	5,132,611
Non-U.S.		958,214		1,749,201
	$	12,039,971	$	6,881,812

Reconciliation of Income Tax Provision Computed at Statutory Rates

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision is as follows:

	Nine Months Ended December 31, 2016			Year Ended March 31, 2016
Statutory tax rate		34.00	%		34.00	%
Net loss before income taxes	$	12,039,971		$	(6,882,812	)
Expected income tax recovery	$	(4,093,591	)	$	(2,340,000	)
Increase (decrease) in income tax recovery resulting from:
Derivative liability		843,168			(708,000	)
Share based payments		467,183			419,000
Other permanent difference		(419,782	)		49,000
Effect of change in statutory rate		—			(147,000	)
Effect of over provision in prior year		—			(2,164,000	)
Foreign income taxed at foreign rate		76,654			100,000
Increase in valuation allowance		3,126,368			4,791,000
Income tax expense	$	—		$	—

Components of Deferred Income Tax Assets and Liabilities

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows:

	December 31, 2016			March 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$	7,626,208		$	4,915,000
Tax credits		702,153			—
Stock compensation		1,726,293			1,725,000
Other		169,968			609,000
Valuation allowance		(10,224,622	)		(7,249,000	)
Net deferred income tax asset	$	—		$	—

Description of Business - Additional Information (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Jun. 13, 2014
Description Of Business [Line Items]
Date of incorporation	Mar. 13, 2014
Cash and cash equivalents	$ 2,668,655	$ 4,350,350	$ 2,643,937	$ 418,893
Net loss	12,039,971	$ 3,051,492	6,881,812
Accumulated deficit	$ 38,345,234		$ 26,305,263
Neurohabilitation Corporation
Description Of Business [Line Items]
Acquisition percentage of issued and outstanding shares					100.00%
Goodwill					$ 0

Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Dec. 31, 2016 Segment
Number of operating segment	1
Minimum
Effective income tax rate	50.00%

Significant Accounting Policies - Summary of Derivative Liability for Non-employee Stock Options (Details) - Fair Value, Measurements, Recurring - Black Scholes Model - USD ($)	Dec. 31, 2016	Mar. 31, 2016
Non-employee Stock Options
Liabilities:
Fair value, liabilities	$ 1,616,739	$ 521,179
Warrants
Liabilities:
Fair value, liabilities	2,857,061	1,204,581
Level 3 \| Non-employee Stock Options
Liabilities:
Fair value, liabilities	1,616,739	521,179
Level 3 \| Warrants
Liabilities:
Fair value, liabilities	$ 2,857,061	$ 1,204,581

Significant Accounting Policies - Summary of Basic and Diluted Loss per Share (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Numerator
Net loss	$ (12,039,971)	$ (3,051,492)	$ (6,881,812)
Denominator
Weighted-average common shares outstanding	83,355,095	64,646,096	66,522,564
Basic net loss per share	$ (0.14)	$ (0.05)	$ (0.10)
Numerator
Net loss, basic	$ (12,039,971)		$ (6,881,812)
Effect of dilutive securities: change in fair value of derivative liability			(1,156,002)
Net loss, diluted	$ (12,039,971)		$ (8,037,814)
Denominator
Weighted-average common shares outstanding	83,355,095	64,646,096	66,522,564
Effect of dilutive securities: stock options and warrants			503,980
Weighted average common shares outstanding	83,355,095	65,180,918	67,026,544
Diluted net loss per share	$ (0.14)	$ (0.06)	$ (0.12)

Significant Accounting Policies - Summary of Outstanding Securities Excluded from Computation of Diluted Weighted Shares Outstanding (Details) - shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	19,931,262	18,848,369
Options Outstanding
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	9,845,000	5,875,360
Warrants Outstanding
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	10,086,262	12,973,009

Promissory Note - Additional Information (Details) - Promissory Note - USD ($)			9 Months Ended
	Oct. 28, 2015	Aug. 25, 2015	Dec. 31, 2016
Debt Instrument [Line Items]
Principal amount		$ 200,000
Debt instrument, payment terms			The promissory note was to be repaid six months from the date of issuance with interest accruing at the rate of 6% per annum. In addition, the lender was entitled to receive 30,000 common shares of the Company’s common stock on the date of the promissory note and an additional 30,000 common shares every three months thereafter as long as the principal of the loan remained outstanding.
Term of notes		6 months
Interest rate		6.00%
Additional common shares to be issued periodically until loan outstanding		30,000
Common shares issued that were owed the lender	30,000

Convertible Note - Additional Information (Details)				9 Months Ended		12 Months Ended
Convertible Note - Additional Information (Details)	Dec. 29, 2015 USD ($) $ / shares shares	Nov. 10, 2015 USD ($) $ / shares shares	Oct. 09, 2015 USD ($) $ / shares	Dec. 31, 2016 USD ($) Instrument	Dec. 31, 2015 USD ($) shares	Mar. 31, 2016 USD ($)
Convertible Note [Line Items]
Fair value of warrants				$ 1,652,480		$ (331,553)
Gain on extinguishment of debt				$ 0	$ 268,334	268,334
Asset Purchase Agreement \| A&B Company Limited
Convertible Note [Line Items]
Convertible promissory note			$ 7,000,000
$2.0 million note
Convertible Note [Line Items]
Warrant exercisable price per share \| $ / shares		$ 1.44
Warrants exercisable period		3 years
Debt conversion, converted instrument, shares issued \| shares		2,083,333			2,083,333
Common stock conversion price per share \| $ / shares		$ 0.96
Warrants issued upon conversion \| shares					1,041,667
Debt conversion, original debt, amount		$ 2,000,000			$ 2,000,000
$2.0 million note \| A&B Company Limited
Convertible Note [Line Items]
Debt discount			425,208
Accretion in respect of debt discount			0
$2.0 million note \| Asset Purchase Agreement \| A&B Company Limited
Convertible Note [Line Items]
Convertible promissory note			$ 2,000,000
Interest rate			6.00%
Convertible note, maturity date			Apr. 09, 2016
Unsecured convertible conversion price debt per unit \| $ / shares			$ 0.96
Debt conversion description				Each unit would consist of one share of common stock and one half share purchase warrant
Warrant exercisable price per share \| $ / shares		$ 1.44	$ 1.44
Warrants exercisable period		3 years	3 years
Debt conversion, converted instrument, shares issued \| shares		2,083,333
Common stock conversion price per share \| $ / shares		$ 0.96
Warrants issued upon conversion \| shares		1,041,667
Fair value of warrants		$ 206,667
Number of convertible Instruments \| Instrument				2
Gain on extinguishment of debt						$ 268,334
Additional funding commitment
Convertible Note [Line Items]
Warrant exercisable price per share \| $ / shares	$ 1.35
Warrants exercisable period	3 years
Debt conversion, converted instrument, shares issued \| shares	5,555,556
Common stock conversion price per share \| $ / shares	$ 0.90
Debt conversion, original debt, amount	$ 5,000,000
Additional funding commitment \| Asset Purchase Agreement
Convertible Note [Line Items]
Debt conversion description				Each unit would consist of one shares of common stock of the Company and one half share purchase warrant.
Warrant exercisable price, premium percentage				50.00%
Additional funding commitment \| Asset Purchase Agreement \| A&B Company Limited
Convertible Note [Line Items]
Convertible promissory note			$ 5,000,000
Convertible note of issuance period			6 months
Warrant exercisable price per share \| $ / shares	$ 1.35
Warrants exercisable period	3 years
Debt conversion, converted instrument, shares issued \| shares	5,555,556
Common stock conversion price per share \| $ / shares	$ 0.90
Warrants issued upon conversion \| shares	2,777,778
Fair value of warrants	$ 796,945
Debt conversion, original debt, amount	$ 5,000,000

Common Stock and Warrants - Additional Information (Details)													9 Months Ended			12 Months Ended
	Jun. 06, 2016 USD ($) shares	May 02, 2016 USD ($) shares	May 02, 2016 $ / shares shares	Apr. 18, 2016 USD ($) shares	Apr. 18, 2016 $ / shares shares	Dec. 29, 2015 USD ($) $ / shares shares	Nov. 10, 2015 USD ($) $ / shares shares	Jul. 17, 2015 USD ($) $ / shares shares	Jun. 26, 2015 USD ($) $ / shares shares	Apr. 30, 2015 USD ($) $ / shares shares	Jun. 13, 2014 shares	May 30, 2014 USD ($) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2016 $ / shares	Dec. 31, 2015 USD ($) shares	Mar. 31, 2016 USD ($)	May 30, 2014 $ / shares shares
Schedule Of Stockholders Equity [Line Items]
Class A common share, voting rights													One vote per share
Class A common share, dividends declared \| $													$ 0
Cash commission paid to agent \| $													$ 1,508,919		$ 141,100	$ 141,000
Weighted average fair value of the warrants issued, per share \| $ / shares														$ 0.50
Weighted average fair value of compensation options issued , per share \| $ / shares														0.93
$2.0 million note
Schedule Of Stockholders Equity [Line Items]
Warrants exercisable period							3 years
Warrant exercisable price per share \| $ / shares							$ 1.44
Debt conversion, original debt, amount \| $							$ 2,000,000								$ 2,000,000
Debt conversion, converted instrument, shares issued							2,083,333								2,083,333
Common stock conversion price per share \| $ / shares							$ 0.96
Warrants exercisable							1,041,667
Additional funding commitment
Schedule Of Stockholders Equity [Line Items]
Warrants exercisable period						3 years
Warrant exercisable price per share \| $ / shares						$ 1.35
Debt conversion, original debt, amount \| $						$ 5,000,000
Debt conversion, converted instrument, shares issued						5,555,556
Common stock conversion price per share \| $ / shares						$ 0.90
Warrants exercisable						2,777,778
Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares														$ 1.50
Warrants expiration date													Apr. 18, 2019
Private Placement
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares																	$ 0.50
Number of shares issued in transaction												15,240,000
Proceeds from issuance of units \| $												$ 7,016,002
Description of units issued													Each unit consisted of one common share of the Company and one-half of a share purchase warrant.
Warrants exercisable period												2 years
Warrant exercisable price per share \| $ / shares																	$ 1.00
Number of common stock converted by each warrant																	1
Proceeds received from exercise of outstanding warrants \| $	$ 1,397,679
Exercise of outstanding warrants	1,825,600
Warrants expired unexercised	6,604,400
Private Placement \| Additional Paid-In Capital
Schedule Of Stockholders Equity [Line Items]
Gross proceeds of warrants issued \| $												$ 578,961
First Financing
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares										$ 2.15
Number of shares issued in transaction										849,273
Proceeds from issuance of units \| $										$ 1,825,937
Description of units issued													Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”).
Finders fee paid in cash \| $										$ 84,074
First Financing \| First Financing Warrant
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares										$ 3.00
Number of common stock converted by each warrant										1
Warrants expiration period										36 months
First Financing \| First Financing Finder’s Warrants
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares										$ 3.00
Number of common stock converted by each warrant										1
Warrants expiration period										36 months
Warrants issued										27,396
Second Financing
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares									$ 2.15
Number of shares issued in transaction									335,463
Proceeds from issuance of units \| $									$ 721,243
Description of units issued													Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”).
Finders fee paid in cash \| $									$ 40,803
Second Financing \| Second Financing Warrant
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares									$ 3.00
Number of common stock converted by each warrant									1
Warrants expiration period									36 months
Second Financing \| Second Financing Finder’s Warrants
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares									$ 2.15
Number of common stock converted by each warrant									1
Warrants expiration period									60 months
Warrants issued									18,978
Third Financing
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares								$ 2.15
Number of shares issued in transaction								125,756
Proceeds from issuance of units \| $								$ 270,375
Description of units issued													Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”).
Finders fee paid in cash \| $								$ 16,223
Third Financing \| Third Financing Warrant
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares								$ 3.00
Number of common stock converted by each warrant								1
Warrants expiration period								36 months
Third Financing \| Third Financing Finder’s Warrants
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares								$ 2.15
Number of common stock converted by each warrant								1
Warrants expiration period								60 months
Warrants issued								7,545
Short Form Prospectus Offering in Canada and U.S. Private Placement
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares					$ 1.00
Proceeds from issuance of units \| $				$ 7,184,190
Description of units issued													Each Unit consists of one Class A common share in the capital of the Company (a “Common Share’) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”).
Warrant exercisable price per share \| $ / shares					$ 1.50
Number of common stock converted by each warrant					1
Cash commission paid to agent \| $				$ 340,250
Options exercisable to purchase units				436,050
Options exercise price per unit \| $ / shares					$ 1.00
Offering expiration period				24 months
Other cash issuance costs related to offering \| $				$ 1,116,545
Short Form Prospectus Offering in Canada and U.S. Private Placement \| Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Warrants expiration date													Apr. 18, 2019
Over-Allotment Option
Schedule Of Stockholders Equity [Line Items]
Price per share \| $ / shares			$ 1.00
Number of shares issued in transaction		1,090,125
Proceeds from issuance of units \| $		$ 8,052,911
Description of units issued													Each Over-Allotment Unit consists of one Class A common share in the capital of the Company (an “Over-Allotment Common Share”) and one half of one Common Share purchase warrant (each whole warrant, an “Over-Allotment Warrant”).
Warrant exercisable price per share \| $ / shares			$ 1.50
Number of common stock converted by each warrant			1
Cash commission paid to agent \| $		$ 52,124
Options exercisable to purchase units		65,407
Options exercise price per unit \| $ / shares			$ 1.00
Offering expiration period		24 months
Gross proceeds from issuance of units \| $		$ 868,721
Over-Allotment Option \| Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Warrants expiration date													Apr. 18, 2019
Neurohabilitation Corporation
Schedule Of Stockholders Equity [Line Items]
Shares issued to shareholders											35,300,083

Common Stock and Warrants - Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions (Details)	9 Months Ended	12 Months Ended
	Dec. 31, 2016 $ / shares	Mar. 31, 2016 $ / shares	Dec. 31, 2016 $ / shares
Warrants Granted
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price			$ 1.09
Exercise price			$ 1.50
Expected life	3 years
Expected volatility	83.83%
Risk-free interest rate	0.60%
Dividend rate	0.00%
Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 1.38	$ 0.78
Exercise price	$ 1.62	$ 1.62
Expected life	1 year 10 months 21 days	2 years 7 months 24 days
Expected volatility	94.97%	83.86%
Risk-free interest rate	0.79%	0.83%
Dividend rate	0.00%	0.00%

Common Stock and Warrants - Fair Value of Compensation Options Granted Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions (Details) - Options	9 Months Ended
	Dec. 31, 2016 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 1.36
Exercise price	$ 1.00
Expected life	2 years
Expected volatility	126.76%
Risk-free interest rate	0.61%
Dividend rate	0.00%

Common Stock and Warrants - Summary of Warrants Exercise Price Accounted for as Liabilities (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair value of warrants at beginning of period	$ 1,204,581
Issuance of warrants		$ 1,536,134
Fair value of warrants	1,652,480	(331,553)
Fair value of warrants at end of period	$ 2,857,061	$ 1,204,581

Common Stock and Warrants - Summary of Warrant Activity (Details)	9 Months Ended
	Dec. 31, 2016 $ / shares shares	Dec. 31, 2016 $ / shares shares
CAD
Class Of Warrant Or Right [Line Items]
Number of Warrants, Outstanding, beginning balance \| shares	8,430,000	8,430,000
Number of Warrants, Granted \| shares	5,152,938	5,152,938
Number of Warrants, Granted (Agent Compensation) \| shares	501,457	501,457
Number of Warrants, Expired \| shares	(6,604,400)	(6,604,400)
Number of Warrants, Exercised \| shares	(1,922,342)	(1,922,342)
Number of Warrants, Outstanding, ending balance \| shares	5,557,653	5,557,653
Weighted-Average Exercise Price, Outstanding, beginning balance \| $ / shares		$ 1.00
Weighted-Average Exercise Price, Granted \| $ / shares		1.50
Weighted-Average Exercise Price, Granted (Agent Compensation) \| $ / shares		1.00
Weighted-Average Exercise Price, Expired \| $ / shares		1.00
Weighted-Average Exercise Price, Exercised \| $ / shares		1.02
Weighted-Average Exercise Price, Outstanding, ending balance \| $ / shares		$ 1.46
USD
Class Of Warrant Or Right [Line Items]
Number of Warrants, Outstanding, beginning balance \| shares	4,528,609	4,528,609
Number of Warrants, Outstanding, ending balance \| shares	4,528,609	4,528,609
Weighted-Average Exercise Price, Outstanding, beginning balance \| $ / shares	$ 1.62
Weighted-Average Exercise Price, Outstanding, ending balance \| $ / shares	$ 1.62

Common Stock and Warrants - Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Dec. 31, 2016 $ / shares shares	Dec. 31, 2016 $ / shares shares
Warrants Expiration Date, April 30, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	452,032	452,032
Warrant exercisable price per share \| $ / shares	$ 3.00
Expiration Date	Apr. 30, 2018
Warrants Expiration Date, June 26, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	167,731	167,731
Warrant exercisable price per share \| $ / shares	$ 3.00
Expiration Date	Jun. 26, 2018
Warrants Expiration Date, June 26, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	18,978	18,978
Warrant exercisable price per share \| $ / shares	$ 2.15
Expiration Date	Jun. 26, 2020
Warrants Expiration Date, July 17, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	62,878	62,878
Warrant exercisable price per share \| $ / shares	$ 3.00
Expiration Date	Jul. 17, 2018
Warrants Expiration Date, July 17, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	7,545	7,545
Warrant exercisable price per share \| $ / shares	$ 2.15
Expiration Date	Jul. 17, 2020
Warrants Expiration Date, November 10, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	1,041,667	1,041,667
Warrant exercisable price per share \| $ / shares	$ 1.44
Expiration Date	Nov. 10, 2018
Warrants Expiration Date, December 29, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	2,777,778	2,777,778
Warrant exercisable price per share \| $ / shares	$ 1.35
Expiration Date	Dec. 29, 2018
Warrants Expiration Date, April 18, 2019
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	5,056,946	5,056,946
Warrant exercisable price per share \| $ / shares		$ 1.50
Expiration Date	Apr. 18, 2019
Warrants Expiration Date, April 18, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding \| shares	500,707	500,707
Warrant exercisable price per share \| $ / shares		$ 1.00
Expiration Date	Apr. 18, 2018

Share Based Payments - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Aug. 08, 2016	Jun. 18, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised	$ 117,530	$ 19,832
Unrecognized compensation cost related to non-vested stock options outstanding	$ 1,263,767
Weighted-average remaining vesting period	1 year 4 months 28 days
Expected forfeiture rate	0.00%	0.00%
2014 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized and approved to issue under plan				12,108,016
2016 Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized and approved to issue under plan			15,000,000
2014 Stock Incentive Plan and 2016 Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock remaining available for grant	16,958,376

Share Based Payments - Summary of Stock Option Activity (Details)	9 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($) shares	Dec. 31, 2016 CAD ($) $ / shares shares	Mar. 31, 2016 USD ($) shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Beginning balance outstanding \| shares	6,675,360	6,675,360
Number of Options, Granted \| shares	3,535,000	3,535,000
Number of Options, Forfeited \| shares	(31,250)	(31,250)
Number of Options, Cancelled \| shares	(124,110)	(124,110)
Number of Options, Exercised \| shares	(210,000)	(210,000)
Number of Options, Ending balance outstanding \| shares	9,845,000	9,845,000	6,675,360
Number of Options, Exercisable \| shares		6,763,502
Weighted Average Exercise Price, Beginning balance outstanding \| $ / shares		$ 1.08
Weighted Average Exercise Price, Granted \| $ / shares		1.38
Weighted Average Exercise Price, Forfeited \| $ / shares		0.60
Weighted Average Exercise Price, Cancelled \| $ / shares		0.60
Weighted Average Exercise Price, Exercised \| $ / shares		0.60
Weighted Average Exercise Price, Ending balance outstanding \| $ / shares		1.20
Weighted Average Exercise Price, Exercisable \| $ / shares		$ 1.16
Aggregate Intrinsic Value, Beginning balance outstanding \| $		$ 1,580,883
Aggregate Intrinsic Value, Exercised \| $	$ 117,530		$ 19,832
Aggregate Intrinsic Value, Ending balance outstanding \| $		8,218,150
Aggregate Intrinsic Value, Exercisable \| $		$ 6,243,040

Share Based Payments - Summary of Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	9,845,000	6,675,360
Exercise Price	$ 1.20	$ 1.08
Number of Options Exercisable	6,763,502
Option One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	3,310,000
Expiration Date	Jun. 18, 2019
Options Outstanding Remaining Contractual Life (In Years)	2 years 5 months 16 days
Exercise Price	$ 0.60
Grant Date Fair Value	$ 0.26
Number of Options Exercisable	3,310,000
Option Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	100,000
Expiration Date	Jul. 14, 2017
Options Outstanding Remaining Contractual Life (In Years)	6 months 11 days
Exercise Price	$ 2.52
Grant Date Fair Value	$ 1.05
Number of Options Exercisable	100,000
Option Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	450,000
Expiration Date	Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)	2 years 11 months 9 days
Exercise Price	$ 2.92
Grant Date Fair Value	$ 1.65
Number of Options Exercisable	450,000
Option Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	100,000
Expiration Date	Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)	2 years 11 months 9 days
Exercise Price	$ 2.92
Grant Date Fair Value	$ 1.31
Number of Options Exercisable	100,000
Option Five
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	400,000
Expiration Date	Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)	2 years 11 months 9 days
Exercise Price	$ 2.96
Grant Date Fair Value	$ 1.29
Number of Options Exercisable	400,000
Option Six
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	100,000
Expiration Date	Mar. 16, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 2 months 16 days
Exercise Price	$ 3.20
Grant Date Fair Value	$ 1.42
Number of Options Exercisable	66,667
Option Seven
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	50,000
Expiration Date	Aug. 15, 2015
Options Outstanding Remaining Contractual Life (In Years)	3 years 7 months 13 days
Exercise Price	$ 0.98
Grant Date Fair Value	$ 0.39
Number of Options Exercisable	33,334
Option Eight
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	750,000
Expiration Date	Oct. 21, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 9 months 22 days
Exercise Price	$ 0.87
Grant Date Fair Value	$ 0.36
Number of Options Exercisable	375,000
Option Nine
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	550,000
Expiration Date	Oct. 28, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 9 months 29 days
Exercise Price	$ 0.84
Grant Date Fair Value	$ 0.44
Number of Options Exercisable	550,000
Option Ten
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	400,000
Expiration Date	Oct. 28, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 9 months 29 days
Exercise Price	$ 0.84
Grant Date Fair Value	$ 0.36
Number of Options Exercisable	176,000
Option Eleven
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	100,000
Expiration Date	Dec. 31, 2020
Options Outstanding Remaining Contractual Life (In Years)	4 years
Exercise Price	$ 1.24
Grant Date Fair Value	$ 0.50
Number of Options Exercisable	66,668
Option Twelve
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	3,025,000
Expiration Date	Jul. 13, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 6 months 11 days
Exercise Price	$ 1.39
Grant Date Fair Value	$ 0.65
Number of Options Exercisable	1,008,333
Option Thirteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	100,000
Expiration Date	Aug. 08, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 7 months 10 days
Exercise Price	$ 1.31
Grant Date Fair Value	$ 0.65
Number of Options Exercisable	25,000
Option Fourteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	410,000
Expiration Date	Oct. 03, 2020
Options Outstanding Remaining Contractual Life (In Years)	3 years 9 months 4 days
Exercise Price	$ 1.35
Grant Date Fair Value	$ 0.80
Number of Options Exercisable	102,500

Share Based Payments - Schedule of Fair Value of Employee and Director Stock Options Granted Estimated Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions (Details) - Employee and Director Stock Options [Member] - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 1.39	$ 0.82
Exercise price	$ 1.39	$ 0.87
Expected life	2 years 6 months	3 years 9 months
Expected volatility	77.92%	67.85%
Risk-free interest rate	0.49%	0.63%
Dividend rate	0.00%	0.00%

Share Based Payments - Summary of Non-Employee Stock Options Accounted for As Liabilities (Details) - Non-Employee Stock Option [Member] - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of non-employee stock options at beginning of period	$ 521,179	$ 1,581,444
Reallocation of vested non-employee stock options	268,135	690,885
Change in fair value of non-employee stock options during the period	827,425	(1,751,150)
Fair value of non-employee stock options at end of period	$ 1,616,739	$ 521,179

Share Based Payments - Schedule of Fair Value of Non-Employee Liability Classified Award Estimated Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions (Details) - Non-Employee Stock Option [Member] - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 1.92	$ 0.97
Exercise price	$ 1.23	$ 1.52
Expected life	2 years 7 months 2 days	3 years 2 months 23 days
Expected volatility	87.61%	84.62%
Risk-free interest rate	0.79%	0.53%
Dividend rate	0.00%	0.00%

Share Based Payments - Summary of Stock Based Compensation Expense is Classified in Statement of Operations and Comprehensive Loss (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,461,646	$ 1,231,250
Research and Development Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	106,932	158,396
General and Administrative Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,354,714	$ 1,072,854

Income Taxes - Components of Net Loss for Income Tax (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Components Of Income Tax Expense Benefit Continuing Operations [Abstract]
U.S	$ 11,081,757	$ 5,132,611
Non-U.S.	958,214	1,749,201
Loss before income taxes	$ 12,039,971	$ 6,881,812

Income Taxes - Reconciliation of Income Tax Provision Computed at Statutory Rates (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Statutory tax rate	34.00%	34.00%
Net loss before income taxes	$ 12,039,971	$ (6,882,812)
Expected income tax recovery	(4,093,591)	(2,340,000)
Increase (decrease) in income tax recovery resulting from:
Derivative liability	843,168	(708,000)
Share based payments	467,183	419,000
Other permanent difference	(419,782)	49,000
Effect of change in statutory rate		(147,000)
Effect of over provision in prior year		(2,164,000)
Foreign income taxed at foreign rate	76,654	100,000
Increase in valuation allowance	$ 3,126,368	$ 4,791,000

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Mar. 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$ 7,626,208	$ 4,915,000
Tax credits	702,153
Stock compensation	1,726,293	1,725,000
Other	169,968	609,000
Valuation allowance	$ (10,224,622)	$ (7,249,000)

Income Taxes - Additional Information (Details)	9 Months Ended
Income Taxes - Additional Information (Details)	Dec. 31, 2016 USD ($)
Income Taxes [Line Items]
Net operating loss, domestic	$ 21,335,527
Operating loss carry forwards expiration year	2033
Accrual relating to uncertain tax positions	$ 0
Canada [Member]
Income Taxes [Line Items]
Accumulated non-capital losses in Canada	$ 2,707,393

Commitment and Contingencies - Additional Information (Details) - USD ($)		1 Months Ended	9 Months Ended		12 Months Ended	34 Months Ended
	Jan. 22, 2013	Nov. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Research and development expense			$ 4,722,584	$ 2,664,063	$ 3,645,796
Advanced NeuroRehabilitation, LLC \| License Agreement for Exclusive Right on Patent Pending Technology
Commitments And Contingencies [Line Items]
Issuance of common stock for license agreement	16,035,026
Percentage of royalty on net revenue	4.00%
Ximedica, LLC \| Commercial Development-to-supply Program
Commitments And Contingencies [Line Items]
Multi-phased development program contracted amount						$ 5,900,000
Research and development expense			1,647,968		$ 120,448	6,959,784
A&B Company Limited \| Asset Purchase Agreement
Commitments And Contingencies [Line Items]
Contract penalty payable on failure to obtain FDA clearance			$ 2,000,000			$ 2,000,000
Altair LLC
Commitments And Contingencies [Line Items]
Percentage of royalty on sales		7.00%

Related Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2016	Dec. 31, 2016	Mar. 31, 2016
Related Party Transaction [Line Items]
Consulting fee owed to directors		$ 2,550	$ 3,450
Non-employee stock-based compensation expense (benefit)		648,208	(195,709)
Directors
Related Party Transaction [Line Items]
Consulting fees paid		$ 97,829	$ 64,210
Montel Media, Inc. \| Minimum
Related Party Transaction [Line Items]
MPJ Healthcare, LLC beneficially owns common stock percentage		5.00%
Montel Media, Inc. \| Consulting Agreement
Related Party Transaction [Line Items]
Consulting fees paid		$ 135,000
Consulting monthly fee	$ 15,000

Sole-Source Cost-Sharing Agreement - Additional Information (Details) - USAMRMC - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Schedule Of Cost Sharing Agreement [Line Items]
Expiration date of original contract	Dec. 31, 2016
Extended expiration date of original contract	Dec. 31, 2017
Reimbursement received	$ 1,818,249
Maximum
Schedule Of Cost Sharing Agreement [Line Items]
Reimbursable trial cost		$ 2,996,244

Supplemental Cash Flow Information - Additional Information (Details) - USD ($)		9 Months Ended		12 Months Ended
	Nov. 10, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Supplemental Cash Flow Information [Line Items]
Fair value of warrants issued to agent for services in conjunction with the offering		$ 366,271
Proceeds from issuance of common stock		150,000
Common stock shares issued				30,000
Fair value of common stock			$ 23,959	$ 29,045
Gain on extinguishment of debt		$ 0	$ 268,334	268,334
Common stock shares issued			30,000
Fair value of warrants issued at their inception				206,667
Fair value of non-employee vested options reallocated from additional paid-in capital to derivative liability			$ 690,885
$2.0 million note
Supplemental Cash Flow Information [Line Items]
Fair value of common stock			$ 1,525,000
Debt conversion, converted instrument, shares issued	2,083,333		2,083,333
Debt conversion, original debt, amount	$ 2,000,000		$ 2,000,000
Warrants issued upon conversion			1,041,667
Fair value of warrants issued at their inception			$ 206,667
A&B Credit Facility
Supplemental Cash Flow Information [Line Items]
Conversion of draw down				5,000,000
Fair value of warrants issued				1,003,612
Gain on extinguishment of debt				268,334
A&B Credit Facility \| Warrants
Supplemental Cash Flow Information [Line Items]
Conversion of convertible notes into warrants				2,000,000
Private Placement
Supplemental Cash Flow Information [Line Items]
Fair value of warrants issued				$ 532,522

Subsequent Events - Additional Information (Details)		1 Months Ended		9 Months Ended		12 Months Ended
Subsequent Events - Additional Information (Details)	Feb. 14, 2017 USD ($)	Mar. 31, 2017 USD ($) ft²	Feb. 28, 2017 CAD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)	Mar. 31, 2016 USD ($)
Subsequent Event [Line Items]
Proceeds from issuance of common stock, net of issuance costs				$ 7,902,912	$ 7,832,436	$ 7,777,910
Common Stock
Subsequent Event [Line Items]
Issuance of common stock in public offering and private placement, Shares \| shares				10,305,125
Subsequent Event
Subsequent Event [Line Items]
Loss contingency, description	On February 14, 2017, Mackie Research Capital Corporation (“Mackie”), a Canadian investment banking firm, filed a statement of claim in the Ontario Superior Court of Justice naming the Company as defendant. The claim alleges that the Company breached a term of the agency agreement dated March 23, 2016 between the Company and Mackie in connection with its public offering of Class A Common Stock, which closed on February 16, 2017 by not complying with Mackie’s right of first refusal to serve as the lead underwriter in the offering. The Company believes that it fully complied with its obligations under the agency agreement by offering Mackie the opportunity to serve as lead underwriter in the offering. The claim seeks damages totaling $1,400,000 and equitable relief. As the matter is at a preliminary stage, the Company has not been able to make a full assessment on the merits of the claim. The Company intends to defend itself vigorously. In March 2017, the Company entered into a lease for 10,444 square feet of dedicated office space at 642 Newtown-Yardley Road, Suite 100, Newtown, PA 18940. The lease commences on July 1, 2017 and terminates on December 31, 2022 with an option to extend until 2027. Monthly rent plus utilities is approximately $20,018 per month with a 3% annual increase.
Lawsuit filing date	February 14, 2017
Name of plaintiff	Mackie Research Capital Corporation (“Mackie”), a Canadian investment banking firm
Public offering closure date	Feb. 16, 2017
Loss contingency, damages total value	$ 1,400,000
Lease office space \| ft²		10,444
Lease commencement date		Jul. 01, 2017
Lease termination date		Dec. 31, 2022
Lease option to extend termination year		2027
Lease monthly rent plus utilities		$ 20,018
Lease annual increase in rental percentage		3.00%
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Issuance of common stock in public offering and private placement, Shares \| shares			6,555,000
Proceeds from issuance of common stock, net of issuance costs			$ 12,454,500